Individualized tumor response testing profile has a prognostic value in childhood acute leukemias: multicenter non-interventional long-term follow-up study

References

• Pui CH, Robison LL, Look AT. Acute lymphoblastic leukaemia. Lancet 2008;371:1030–1043.
   PubMed Web of Science ®Google Scholar
• Coenen EA, Raimondi SC, Harbott J, et al. Prognostic significance of additional cytogenetic aberrations in 733 de novo pediatric 11q23/MLL-rearranged AML patients: results of an international study. Blood 2011;117:7102–7111.
   PubMed Web of Science ®Google Scholar
• Creutzig U, Zimmermann M, Bourquin JP, et al. Second induction with high-dose cytarabine and mitoxantrone: different impact on pediatric AML patients with t(8;21) and with inv(16). Blood 2011;118:5409–5415.
   PubMed Web of Science ®Google Scholar
• Pieters R, Huismans DR, Loonen AH, et al. Relation of cellular drug resistance to long-term clinical outcome in childhood acute lymphoblastic leukaemia. Lancet 1991;338:399–403.
   PubMed Web of Science ®Google Scholar
• Holleman A, Cheok MH, den Boer ML, et al. Gene-expression patterns in drug-resistant acute lymphoblastic leukemia cells and response to treatment. N Engl J Med 2004;351:533–542.
   PubMed Web of Science ®Google Scholar
• Bhojwani D, Kang H, Menezes RX, et al. Gene expression signatures predictive of early response and outcome in high-risk childhood acute lymphoblastic leukemia: a Children's Oncology Group study [corrected]. J Clin Oncol 2008;26:4376–4384.
   PubMed Web of Science ®Google Scholar
• Lonnerholm G, Thorn I, Sundstrom C, et al. In vitro cellular drug resistance adds prognostic information to other known risk-factors in childhood acute lymphoblastic leukemia. Leuk Res 2011;35: 472–478.
   PubMed Web of Science ®Google Scholar
• Moricke A, Reiter A, Zimmermann M, et al. Risk-adjusted therapy of acute lymphoblastic leukemia can decrease treatment burden and improve survival: treatment results of 2169 unselected pediatric and adolescent patients enrolled in the trial ALL-BFM 95. Blood 2008;111:4477–4489.
   PubMed Web of Science ®Google Scholar
• Schrappe M, Valsecchi MG, Bartram CR, et al. Late MRD response determines relapse risk overall and in subsets of childhood T-cell ALL: results of the AIEOP-BFM-ALL 2000 study. Blood 2011 ;118:2077–2084.
   PubMed Web of Science ®Google Scholar
• Escherich G, Troger A, Gobel U, et al. The long-term impact of in vitro drug sensitivity on risk stratification and treatment outcome in acute lymphoblastic leukemia of childhood (CoALL 06-97). Haematologica 2011;96:854–862.
   PubMed Web of Science ®Google Scholar
• Den Boer ML, Harms DO, Pieters R, et al. Patient stratification based on prednisolone-vincristine-asparaginase resistance profiles in children with acute lymphoblastic leukemia. J Clin Oncol 2003;21: 3262–3268.
   PubMed Web of Science ®Google Scholar
• Styczynski J, Wysocki M. Is the in vitro drug resistance profile the strongest prognostic factor in childhood acute lymphoblastic leukemia?J Clin Oncol 2004;22:963–964.
   PubMed Web of Science ®Google Scholar
• Bosanquet AG, Nygren P, Weisenthal L. Individualized tumor response testing in leukemia and lymphoma. In: Kaspers GJL, Coiffier B, Heinrich MC, et al., editors. Innovative leukemia and lymphoma therapy. New York: Informa Healthcare; 2008. pp.
   Google Scholar
• Styczynski J, Wysocki M, Dluzniewska A, et al. Prognostic impact of combined fludarabine, treosulfan and mitoxantrone resistance profile in childhood acute myeloid leukemia. Anticancer Res 2008;28: 1927–1931.
   PubMed Web of Science ®Google Scholar
• Steinherz PG, Gaynon PS, Breneman JC, et al. Treatment of patients with acute lymphoblastic leukemia with bulky extramedullary disease and T-cell phenotype or other poor prognostic features: randomized controlled trial from the Children's Cancer Group. Cancer 1998;82:600–612.
   PubMed Web of Science ®Google Scholar
• Pieters R, Schrappe M, De Lorenzo P, et al. A treatment protocol for infants younger than 1 year with acute lymphoblastic leukaemia (Interfant-99): an observational study and a multicentre randomised trial. Lancet 2007;370:240–250.
   PubMed Web of Science ®Google Scholar
• Schrappe M, Reiter A, Ludwig WD, et al. Improved outcome in childhood acute lymphoblastic leukemia despite reduced use of anthracyclines and cranial radiotherapy: results of trial ALL-BFM 90. German-Austrian-Swiss ALL-BFM Study Group. Blood 2000;95: 3310–3322.
   PubMed Web of Science ®Google Scholar
• Mejstrikova E, Fronkova E, Kalina T, et al. Detection of residual B precursor lymphoblastic leukemia by uniform gating flow cytometry. Pediatr Blood Cancer 2010;54:62–70.
   PubMed Web of Science ®Google Scholar
• Dluzniewska A, Balwierz W, Armata J, et al. Twenty years of Polish experience with three consecutive protocols for treatment of childhood acute myelogenous leukemia. Leukemia 2005;19:2117–2124.
   PubMed Web of Science ®Google Scholar
• Styczynski J, Wysocki M, Debski R, et al. Predictive value of multidrug resistance proteins and cellular drug resistance in childhood relapsed acute lymphoblastic leukemia. J Cancer Res Clin Oncol 2007;133:875–893.
   PubMedGoogle Scholar
• Styczynski J, Toporski J, Wysocki M, et al. Fludarabine, treosulfan and etoposide sensitivity and the outcome of hematopoietic stem cell transplantation in childhood acute myeloid leukemia. Anticancer Res 2007;27:1547–1551.
   PubMed Web of Science ®Google Scholar
• Hongo T, Yajima S, Sakurai M, et al. In vitro drug sensitivity testing can predict induction failure and early relapse of childhood acute lymphoblastic leukemia. Blood 1997;89:2959–2965.
   PubMed Web of Science ®Google Scholar
• Frost BM, Nygren P, Gustafsson G, et al. Increased in vitro cellular drug resistance is related to poor outcome in high-risk childhood acute lymphoblastic leukaemia. Br J Haematol 2003;122:376–385.
   PubMed Web of Science ®Google Scholar
• Kaspers GJ, Veerman AJ, Pieters R, et al. In vitro cellular drug resistance and prognosis in newly diagnosed childhood acute lymphoblastic leukemia. Blood 1997;90:2723–2729.
   PubMed Web of Science ®Google Scholar
• Jaworska-Posadzy A, Styczynski J, Kubicka M, et al. Prognostic value of persistent peripheral blood and bone marrow lymphoblasts on day 15 of therapy in childhood acute lymphoblastic leukemia as detected by flow cytometry. Anticancer Res 2011;31:1453–1457.
   PubMed Web of Science ®Google Scholar
• Smith PJ, Lihou MG. Prediction of remission induction in childhood acute myeloid leukemia. Aust NZ J Med 1986;16:39–42.
   PubMedGoogle Scholar
• Dow LW, Dahl GV, Kalwinsky DK, et al. Correlation of drug sensitivity in vitro with clinical responses in childhood acute myeloid leukemia. Blood 1986;68:400–405.
   PubMed Web of Science ®Google Scholar
• Rosanda C, Garaventa A, Pasino M, et al. A short-term in vitro drug sensitivity assay in pediatric malignancies. Anticancer Res 1987;7:365–367.
   PubMed Web of Science ®Google Scholar
• Klumper E, Pieters R, Kaspers GJ, et al. In vitro chemosensitivity assessed with the MTT assay in childhood acute non-lymphoblastic leukemia. Leukemia 1995;9:1864–1869.
   PubMed Web of Science ®Google Scholar
• Miller CB, Zehnbauer BA, Piantadosi S, et al. Correlation of occult clonogenic leukemia drug sensitivity with relapse after autologous bone marrow transplantation. Blood 1991;78:1125–1131.
   PubMed Web of Science ®Google Scholar
• Zwaan CM, Kaspers GJ, Pieters R, et al. Cellular drug resistance profiles in childhood acute myeloid leukemia: differences between FAB types and comparison with acute lymphoblastic leukemia. Blood 2000;96:2879–2886.
   PubMed Web of Science ®Google Scholar
• Zwaan CM, Kaspers GJ, Pieters R, et al. Different drug sensitivity profiles of acute myeloid and lymphoblastic leukemia and normal peripheral blood mononuclear cells in children with and without down syndrome. Blood 2002;99:245–251.
   PubMed Web of Science ®Google Scholar
• Yamada S, Hongo T, Okada S, et al. Clinical relevance of in vitro chemoresistance in childhood acute myeloid leukemia. Leukemia 2001;15:1892–1897.
   PubMed Web of Science ®Google Scholar
• Staib P, Staltmeier E, Neurohr K, et al. Prediction of individual response to chemotherapy in patients with acute myeloid leukaemia using the chemosensitivity index CI. Br J Haematol 2005;128: 783–791.
   PubMed Web of Science ®Google Scholar